Antilipolytic drug boosts glucose metabolism in prostate cancer

Kim Francis Andersen; Vadim Divilov; Jacek Koziorowski; NagaVaraKishore Pillarsetty; Jason S Lewis

doi:10.1016/j.nucmedbio.2013.01.008

Antilipolytic drug boosts glucose metabolism in prostate cancer

Kim Francis Andersen, Vadim Divilov, Jacek Koziorowski, NagaVaraKishore Pillarsetty, Jason S Lewis

Department of Clinical Physiology, Nuclear Medicine & PET

5 Citations (Scopus)

Abstract

The antilipolytic drug Acipimox reduces free fatty acid (FFA) levels in the blood stream. We examined the effect of reduced FFAs on glucose metabolism in androgen-dependent (CWR22Rv1) and androgen-independent (PC3) prostate cancer (PCa) xenografts.

Original language	English
Journal	Nuclear Medicine and Biology
Volume	40
Issue number	4
Pages (from-to)	524-8
Number of pages	5
ISSN	0969-8051
DOIs	https://doi.org/10.1016/j.nucmedbio.2013.01.008
Publication status	Published - May 2013

Access to Document

10.1016/j.nucmedbio.2013.01.008

Cite this

@article{10945e8fe67f4711bd6960cc28bb0a0c,

title = "Antilipolytic drug boosts glucose metabolism in prostate cancer",

abstract = "The antilipolytic drug Acipimox reduces free fatty acid (FFA) levels in the blood stream. We examined the effect of reduced FFAs on glucose metabolism in androgen-dependent (CWR22Rv1) and androgen-independent (PC3) prostate cancer (PCa) xenografts.",

author = "Andersen, {Kim Francis} and Vadim Divilov and Jacek Koziorowski and NagaVaraKishore Pillarsetty and Lewis, {Jason S}",

year = "2013",

month = may,

doi = "10.1016/j.nucmedbio.2013.01.008",

language = "English",

volume = "40",

pages = "524--8",

journal = "Nuclear Medicine and Biology",

issn = "0969-8051",

publisher = "Elsevier Inc",

number = "4",

}

TY - JOUR

T1 - Antilipolytic drug boosts glucose metabolism in prostate cancer

AU - Andersen, Kim Francis

AU - Divilov, Vadim

AU - Koziorowski, Jacek

AU - Pillarsetty, NagaVaraKishore

AU - Lewis, Jason S

PY - 2013/5

Y1 - 2013/5

N2 - The antilipolytic drug Acipimox reduces free fatty acid (FFA) levels in the blood stream. We examined the effect of reduced FFAs on glucose metabolism in androgen-dependent (CWR22Rv1) and androgen-independent (PC3) prostate cancer (PCa) xenografts.

AB - The antilipolytic drug Acipimox reduces free fatty acid (FFA) levels in the blood stream. We examined the effect of reduced FFAs on glucose metabolism in androgen-dependent (CWR22Rv1) and androgen-independent (PC3) prostate cancer (PCa) xenografts.

U2 - 10.1016/j.nucmedbio.2013.01.008

DO - 10.1016/j.nucmedbio.2013.01.008

M3 - Journal article

C2 - 23454248

SN - 0969-8051

VL - 40

SP - 524

EP - 528

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

IS - 4

ER -

Antilipolytic drug boosts glucose metabolism in prostate cancer

Abstract

Access to Document

Fingerprint

Cite this